You are here: Industry Insights > Sanofi

News List

Sanofi builds focus on rare blood disorders and cancers worldpharmanews
November 30, 2018
Rare blood disorders and blood-related cancers continue to be a major focus of research as scientists look for new treatments for serious and life-threatening conditions.
Dupixent and vaccines bring Sanofi back to growth fiercepharma
November 28, 2018
With competition to its diabetes and cardiovascular franchises hurting Sanofi, CEO Olivier Brandicourt pledged a return to growth starting from the second half of 2018. And thanks mainly to Dupixent and now-recovered vaccines sales, he kept his word.
GSK retains leading position on access to medicines list pharmatimes
November 26, 2018
GlaxoSmithKline has retained its top position among a global list of pharmaceutical companies striving to make their medicines, vaccines and diagnostics more accessible for people in low- and middle-income countries.
FDA approves Regeneron, Sanofi's Dupixent for asthma treatment biospectrumasia
November 26, 2018
The FDA approves Regeneron Pharmaceuticals and development partner Sanofi's DUPIXENT (dupilumab) as add-on maintenance therapy in patients with
GSK execs change their tune as AZ, Sanofi heap pressure on respiratory hopeful Nucala fiercepharma
November 11, 2018
On the company’s third-quarter conference call last week, the British drugmaker’s pharma chief, Luke Miels, told investors the company had “very much held” AstraZeneca newcomer Fasenra “in place in Japan and Europe.”
Cell-derived flu vaccine strains a better match than eggs, Seqirus analysis finds fiercepharma
November 09, 2018
Flu vaccine efficacy problems were well documented throughout last year’s harsh season. Now the world’s largest cell-based vaccine producer, Seqirus, has published data
Sanofi's controversial Dengvaxia picks up FDA priority review fiercepharma
November 09, 2018
Sanofi has weathered controversy with its world-first dengue vaccine, Dengvaxia, but the company is pressing ahead, and on Tuesday said the FDA had not only accepted
Sanofi and Regeneron’s Dupixent gets more positive feedback from US FDA expressbpd
November 08, 2018
Dupixent was launched in the US in April 2017 for the treatment of moderate-to-severe eczema
Priority review for Sanofi, Regeneron’s Dupixent pharmatimes
November 08, 2018
Sanofi and Regeneron’s biologic Dupixent has been granted a priority review in the US for use to treat certain adolescent patients with moderate-to-severe atopic dermatitis.
Sanofi signs $1bn drug development deal with Denali Therapeutics pharmaceutical-technology
November 06, 2018
Sanofi has entered a deal valued at more than $1bn with US-based Denali Therapeutics to advance potential drug candidates for the treatment of neurological and systemic inflammatory diseases.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 43 44 Next page